Diagnostics Solutions Strategic Priorities

Diagnostics reporting 2021 onwards Moving from business to customer areas and adjusting regions Old New Roche Changes in regional reporting Changes in customer areas reporting 2020 2019 Change in % 2020 2019 CHFm CHFM CHF CER CHFM CHFM CHF Change in % CER Diagnostics Division 13,791 12,950 6 14 Diagnostics Division 13,791 12,950 6 14 Centralised and Point of Care Solutions 7,273 7,819 -7 -1 Core Lab¹ 6,194 7.078 -12 -6 Molecular Diagnostics 3,760 2,109 78 90 Molecular Lab 3,760 2,109 78 90 Diabetes Care 1,670 1,918 -13 -5 Point of Care 1,079 741 46 54 Tissue Diagnostics 1,088 1,104 -1 5 Pathology Lab 1,088 1,104 -1 5 Diabetes Care 1,670 1,918 -13 -5 North America +26% -28% of divisional sales EMEA² +19% -40% of divisional sales Latin America +74% -6% of divisional sales Japan +5% -4% of divisional sales Asia Pacific -3% -23% of divisional sales CER: Constant Exchange Rates; 1 Includes Roche Information Solutions sales; 2 Europe, Middle East and Africa North America +26% -28% of divisional sales EMEA² +19% -40% of divisional sales Latin America +14% -6% of divisional sales Asia Pacific -2% -26% of divisional sales 12

View entire presentation